Biovica: DiviTum to Stir Some Blood

Initiating Coverage



Redeye initiates coverage of cancer diagnostics firm Biovica with base case of SEK 24. The shares have spiked some 140 percent YTD on the back of increasing investor optimism ahead of a possible US launch next year. While we see room for a slight pull-back short-term, a potential marketing approval in the US for blood-based cancer diagnostic test DiviTum within the next 6-12 months is a major catalyst for significant further upside to our valuation. Ongoing clinical validation to complete the submission to the FDA could provide important clues already in the next few months.


Niklas Elmhammer

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.